Genfit S.A. (GNFTF)
USD 5.55
(0.0%)
USD 5.55
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 62.25 Million EUR | -10.05% |
| 2022 | 69.21 Million USD | -7.83% |
| 2021 | 75.09 Million USD | -64.58% |
| 2020 | 212.03 Million USD | 11.83% |
| 2019 | 189.6 Million USD | 0.49% |
| 2018 | 188.67 Million USD | -1.83% |
| 2017 | 192.18 Million USD | 3541.28% |
| 2016 | 5.27 Million USD | 8.4% |
| 2015 | 4.86 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 59.23 Million USD | 0.0% |
| 2023 Q2 | 68.33 Million USD | -6.91% |
| 2023 Q3 | 65.81 Million USD | -3.69% |
| 2023 Q4 | 62.25 Million EUR | -5.41% |
| 2023 Q1 | 73.4 Million USD | 6.06% |
| 2023 FY | 62.25 Million EUR | -10.05% |
| 2022 Q2 | 69.92 Million USD | 0.0% |
| 2022 FY | 69.21 Million USD | -7.83% |
| 2022 Q3 | 68.78 Million USD | -1.63% |
| 2022 Q4 | 69.21 Million USD | 0.62% |
| 2021 Q2 | 72.68 Million USD | 0.0% |
| 2021 FY | 75.09 Million USD | -64.58% |
| 2021 Q4 | 75.09 Million USD | 0.0% |
| 2020 Q2 | 192.04 Million USD | 0.0% |
| 2020 FY | 212.03 Million USD | 11.83% |
| 2020 Q4 | 212.03 Million USD | 0.0% |
| 2019 Q4 | 201.19 Million USD | 0.0% |
| 2019 FY | 189.6 Million USD | 0.49% |
| 2019 Q2 | 187.94 Million USD | 0.0% |
| 2018 FY | 188.67 Million USD | -1.83% |
| 2017 FY | 192.18 Million USD | 3541.28% |
| 2016 FY | 5.27 Million USD | 8.4% |
| 2015 FY | 4.86 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -197.733% |
| Evofem Biosciences, Inc. | 8000.00 USD | -778062.5% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -3446.212% |
| Mesoblast Limited | 100.29 Million USD | 37.93% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -106057.703% |
| Genus plc | 228.2 Million USD | 72.72% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -9231.479% |
| ContraFect Corporation | 2.21 Million USD | -2716.878% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -4337.343% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -1047.208% |
| MultiCell Technologies, Inc. | 36.43 USD | -170883786.906% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -11.942% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -2696.631% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -4967.973% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 62.522% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -3179.118% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -36256.363% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -1129308.563% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | -127.213% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -19233.23% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.446% |
| Halberd Corporation | 150 Thousand USD | -41402.0% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -20651.0% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -37811.757% |
| argenx SE | 15.35 Million USD | -305.451% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -206.484% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -1396960.144% |
| Genscript Biotech Corporation | 287.12 Million USD | 78.319% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -49189.006% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -27050.215% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -11125.049% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -245969.015% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -653.303% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -23335.541% |
| ONE Bio Corp. | 592.19 Thousand USD | -10412.194% |
| Reve Technologies, Inc. | 1064.00 USD | -5850745.865% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -41509.074% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -41509.074% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -27002.934% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -44051.064% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -77716.25% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -696.078% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -16768.492% |
| International Stem Cell Corporation | 445 Thousand USD | -13889.438% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -663.84% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -13522.101% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -5262.016% |
| PureTech Health plc | 18.25 Million USD | -241.112% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -41402.0% |
| IXICO plc | 275 Thousand USD | -22537.455% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -425.83% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -136.622% |
| CSL Limited | 11.23 Billion USD | 99.446% |
| Cellectis S.A. | 36.21 Million USD | -71.917% |